{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-196808","form_type":"8-K","ticker":"BIIB","cik":"0000875045","company_name":"BIOGEN INC.","filed_at":"2023-07-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.839232+00:00","generated_at":"2026-06-12T23:27:49.532614+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Biogen to acquire Reata for $172.50/share, ~$7.3B enterprise value","bullets":["Deal price $172.50/share in cash; total enterprise value ~$7.3 billion.","Expected closing in Q4 2023; subject to Reata stockholder approval and regulatory clearances.","Biogen to finance with cash on hand plus term debt; voting agreements cover ~36% of Reata shares.","Acquisition expected to be slightly dilutive to Biogen non-GAAP EPS in 2023, neutral in 2024, significantly accretive from 2025.","Reata's SKYCLARYS is the first FDA-approved treatment for Friedreich's ataxia; launch underway, EU review ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-196808","json":"https://secwatch.observer/filing/0001193125-23-196808.json","markdown":"https://secwatch.observer/filing/0001193125-23-196808.md","text":"https://secwatch.observer/filing/0001193125-23-196808.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875045/000119312523196808/0001193125-23-196808-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875045/000119312523196808/d507671d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T23:27:49.532614+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}